INVO Fertility, Inc. filed its quarterly report on Form 10-Q with the SEC on November 16, 2026, covering the fiscal quarter ended September 30, 2026, disclosing consolidated balance sheet figures and other financial information for the period.
Key Highlights
- Shares outstanding: As of November 16, 2026, the company reported 1,192,860 shares of common stock outstanding.
- Total assets: Consolidated total assets were $25,500,200 as of September 30, 2026, compared with $20,220,124 as of December 31, 2025.
- Cash position: Cash was $3,695,770 at September 30, 2026, up from $2,077,842 at December 31, 2025.
- Goodwill: Goodwill increased to $9,236,642 as of September 30, 2026, from $5,878,986 at December 31, 2025.
- Convertible note payable - related party: The current-portion balance fell to $17,882 at September 30, 2026, from $880,000 at December 31, 2025.
- Accounts payable and accrued liabilities: Decreased to $1,297,870 from $2,034,057 at year-end 2025.
INVO Fertility Balance Sheet Changes Through September 30, 2026
According to the filing, INVO Fertility, Inc. (NASDAQ:IVF) reported total assets of $25,500,200 as of September 30, 2026, an increase from $20,220,124 as of December 31, 2025. The company disclosed that cash rose to $3,695,770 from $2,077,842 over the same period. Accounts receivable, net of allowances of $140,089, stood at $170,423 at the close of the quarter, compared with $217,263 net of allowances of $69,641 at year-end 2025.
The filing disclosed that goodwill grew to $9,236,642 as of September 30, 2026, up from $5,878,986 at December 31, 2025, which the company attributed in part to its ongoing fertility clinic acquisition activity. Property and equipment, net, increased to $814,175 from $386,165. The company also reported a lease right-of-use asset of $2,052,056, compared with $1,286,217 at year-end 2025. Intangible assets, net, were $1,245,345 versus $1,325,145 at December 31, 2025. The company's investment in NAYA Therapeutics remained unchanged at $2,466,810, and the note receivable from NAYA Therapeutics increased to $5,240,333 from $5,029,770.
On the liabilities side, the convertible note payable to a related party fell from $880,000 to $17,882, and accounts payable and accrued liabilities declined from $2,034,057 to $1,297,870, according to the filing. Deferred revenue was reported at $728,630, up slightly from $721,897. The filing noted that the company is classified as a non-accelerated filer and a smaller reporting company, and is incorporated in Nevada with principal offices in Sarasota, Florida. The filing contains forward-looking statements that, according to the company, "are not guarantees of future results or performance, and involve substantial risks and uncertainty."
What Was Disclosed
INVO Fertility filed its Form 10-Q for the quarter ended September 30, 2026, disclosing unaudited consolidated balance sheet data showing growth in total assets, cash, and goodwill relative to December 31, 2025, alongside changes in selected liabilities and 1,192,860 shares outstanding as of November 16, 2026.



Please wait processing your request...